... / News / New evidence for the residual immune response towards decellularized human heart valves
Press Release
Friday, 28 January 2022
5-year ESPOIR Trial results and ESPOIR Registry Data to be presented at the DGTHG/DGPK 2022
The 5-year results of the prospective European multi-centre ESPOIR trial will be presented as an on-demand presentation within the 2022 DGTHG/DGPK meeting in Hamburg.
The talk will also focus on the available longterm data from the ESPOIR registry including a matched comparison to the two most widely used other options for pulmonary valve replacement.